Global Tuberculosis Strategies
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles.
As illustrated by Kenneth G. Krul, Phd in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. There are primarily three focal points for the development of strategy for combating tuberculosis: potential market, epidemiology (tuberculosis patient trends) and technology, and Krul reviews how diagnostic and pharmaceutical companies can incorporate these focal points into strategy.
Lack of proper diagnosis is one of the barriers to tuberculosis treatment. Krul goes into detail about screening techniques and the potential market for diagnostic products. In addition, treatment markets are defined for major regions of the world.
Kalorama Information's Global Tuberculosis Strategies, authored by Kalorama Information analyst Kenneth G. Krul, PhD, covers these points in detail and presents the most authoritative look at the global tuberculosis threat, strategies to combat tuberculosis, and the market opportunities that can be created in tuberculosis treatment. As part of its coverage, the report includes:
Extensive Tuberculosis Etiology necessary to understand this unique disease.
Epidemiologic Statistics including 30 Tables of Incidence, Prevalence and Mortality Statistics by Region and by Type of Tuberculosis.
Theoretical Market Sizes for Screening/Diagnosis as well as Treatment by Region and by Type of Tuberculosis (MDR and non-MDR).
Complete overview of Tuberculosis Screening Procedures.
Review of Products used for treatment of Tuberculosis.
A Glossary of Important Terms.
A truly global round-up, the report focuses in detail on the following regions:
Marketing directors, product managers, sales managers and business development executives in both diagnostic and pharmaceutical companies will benefit from this unique resource.